Cost of new cholesterol drugs in spotlight
New York
EXPRESS Scripts Holding Co said on Wednesday that two costly new cholesterol fighters will not be "budget busters" for its clients and that most prescriptions for the potent drugs have been rejected because patients did not meet required medical criteria.
"We're seeing a lot of patients who either don't qualify or their physicians are not providing (needed) information," said Everett Neville, a vice-president of Express Scripts, the largest pharmacy benefit manager in the United States.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead independent director
GSK profit drops 23% in Q1 on higher costs
Starbucks points to weaker consumer as profit falls
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices